

# Factsheet

Bellevue Funds (Lux) | Share class I EUR

Investment Company with Variable Capital (SICAV) according to Luxembourg Laws – UCITS  
Marketing document – for retail and professional investors in AT, DE, LU, UK, ES, IT (Inst.) and non-qualified investors in CH

## Investment focus

The fund's aim is to achieve capital growth in the long term. The Bellevue Asia Pacific Healthcare Fund invests in healthcare stocks of companies that have their registered office or carry out the majority of their economic activity in the healthcare markets of the Asia-Pacific region. Its investment universe consists of generics producers, pharma and biotechnology companies, medical technology and services firms. Experienced sector specialists focus on profitable companies that have a well-established product portfolio. Investments are made based on fundamental research analysis. Stock selection is exclusively bottom up, independent of benchmark weightings. The Fund takes ESG factors into consideration while implementing the aforementioned investment objectives.


## Fund facts

NAV	234.82
Volume	EUR 473.4 mn
NAV-calculation	Daily "Forward Pricing"
Cut off time	9:00 CET
Distribution policy	Accumulating
Investment manager	Bellevue Asset Management AG
Custodian	RBC Investor Services, Luxembourg
Launch date	28.04.2017
Fiscal year end	30.06
Benchmark	MSCI Asia Pacific HC Net TR
ISIN code	LU1587985224
Valor	36225573
Bloomberg	BEAAPIE LX
WKN	A2DPA7
Management fee	0.90%
Performance fee	10% above Benchmark*
Subscription fee	up to 5%
Min. investment	n.a.
Legal entity	Luxembourg UCITS V SICAV
Countries of distribution	AT, CH, DE, LU, UK, ES, IT (Inst.)
EU SFDR 2019/2088	Article 8

## Key figures

Beta	0.73
Correlation	0.8
Volatility	16.1%
Tracking Error	10.75
Active Share	60.38
Sharpe Ratio	0.99
Information Ratio	0.16
Jensen's Alpha	5.81

## Indexed performance since launch



## Cummulated & annualized performance

### Cummulated

	1 month	YTD	1 year	3 years	5 years	Since launch
I EUR	-5.0%	0.4%	2.7%	59.7%	n.a.	87.9%
BM	-4.8%	-5.1%	3.4%	47.0%	n.a.	65.7%
MSCI AP	0.3%	6.4%	16.4%	42.9%	n.a.	39.2%


### Annualized

	1 year	3 years	5 years	Since launch
I EUR	2.7%	16.9%	n.a.	15.0%
BM	3.4%	13.7%	n.a.	11.9%
MSCI AP	16.4%	12.6%	n.a.	7.6%

## Annual performance

	2016	2017	2018	2019	2020	YTD
I EUR	n.a.	n.a.	-4.8%	25.9%	32.2%	0.4%
BM	n.a.	n.a.	0.3%	32.6%	22.2%	-5.1%
MSCI AP	n.a.	n.a.	-9.2%	21.7%	10.0%	6.4%

## Rolling 12-month-performance



Source: Bellevue Asset Management, 31.10.2021; all figures in EUR %, total return / BVI-methodology  
Past performance is not a reliable indicator of future results and can be misleading. As the subfund is denominated in a currency that may differ than an investor's base currency, changes in the rate of exchange may have an adverse effect on prices and incomes. Performance is shown net of fees and expenses for the relevant share class over the reference period. All performance figures reflect the reinvestment of dividends and do not take into account the commissions and costs incurred on the issue and redemption of shares, if any. Individual costs are not taken into account and would have a negative impact on the performance. With an investment amount of EUR 1,000 over an investment period of five years, the investment result in the first year would be reduced by the front-end load of up to EUR 50 (5%) as well as by additional individual custody charges. In subsequent years, the investment result would also be reduced by the individual custody account costs incurred. The reference benchmark of this class is used for performance comparison purposes only (dividend reinvested). No benchmark is directly identical to a subfund, thus the performance of a benchmark is not a reliable indicator of future performance of the subfund it is compared to. There can be no assurance that a return will be achieved or that a substantial loss of capital will not be incurred.

**Top 10 positions**

Olympus		4.5%
CSL		4.1%
Sun Pharmaceutical		4.1%
Cipla		3.6%
Shionogi		3.6%
SZ Mindray		3.2%
Kyowa Hakko Kirin		3.1%
Hygeia Healthcare		3.1%
Jiangsu Hengrui		3.1%
Eisai		3.1%
Total top 10 positions		35.4%
Total positions		43

**Geographic breakdown**

China		36.4%
Japan		26.9%
India		13.8%
South Korea		8.0%
Australia		5.0%
Thailand		2.5%
Cash		7.4%

**Market cap breakdown**

1 - 2 bn		0.5%
2 - 5 bn		6.8%
5 - 15 bn		25.2%
15 - 20 bn		6.5%
> 20 bn		52.5%
Others		8.6%

**Market review**

Stocks as measured by the MSCI World staged a strong comeback in October after giving up some ground in September and advanced almost 6% in USD mom. Despite the continued upward pressure on prices and consequently on nominal bond yields in the wake of supply chain constraints, at the end of the day robust quarterly results announcements led to the positive market sentiment. Year to date, the MSCI World Index is now showing a remarkable 20% return. Stocks in the Asia Pacific region closed the month of October unchanged. Regional healthcare stocks were hit by profit-taking as well as profit warnings from Ping An Healthcare and Ali Health, two Chinese digital health firms. In this context, the regional healthcare sector shed about 5% of its value in USD over the past month.

Takeda reported a major setback in one of its crucial R&D programs, TAK-994, an investigational therapy for patients with narcolepsy. It had to suspend two Phase II trials of TAK-994 due to a "safety signal". Since the safety signal was so serious that it led to the suspension of the trial, it could even bring the entire narcolepsy program to a premature end. This is the second setback in Takeda's R&D pipeline within the space of a few months and it will have a significant impact on the company's mid-term growth prospects.

Ping An Healthcare and Ali Health slashed their medium-term growth targets with the release of their latest quarterly results. Recently introduced Chinese regulations concerning data privacy, patient-related data in particular, have forced these companies to adjust their business models. Their management also said that capital expenditure to fuel future growth would be higher than expected. The announcements put the share prices of both companies under pressure.

Kyowa Kirin presented detailed data from its successful Phase II trial of KHK4083 in patients with moderate to severe atopic dermatitis. Kyowa's therapeutic option may be superior to Dupixent (Sanofi/Regeneron), the current standard of care, which generates annual sales of close to USD 4 bn.

The US pharmaceutical giant Merck demonstrated that its antiviral COVID-19 pill molnupiravir reduces the risk of hospitalization in patients with mild to moderate cases of COVID-19 by 50%. This could represent a huge business opportunity for several Indian pharmaceutical companies. Divi's Laboratories is one of Merck's API (Active Pharmaceutical Ingredient) suppliers and licensing partners in India.

Jiangsu Hengrui, Bangkok Dusit and Pro Medicus were added to the portfolio last month and existing positions in Hygeia, Aier Eye Hospital, Dr. Reddy's and Kyowa Kirin were increased. Takeda, Ping An Healthcare, Glenmark and Cansino Biologics are no longer in the portfolio. Shareholdings of Eisai and Innovent were reduced.

**Positioning & outlook**

Asia is the most dynamic growth region in the world and it accounts for more than half of the world's population. Asian emerging markets are forecast to account for more than 50% of global GDP by 2050. As household incomes rise, the economic growth model of Asian countries will shift from manufacturing to the services sector. A growing middle class fuels demand for modern medicine. Healthcare ranks increasingly high on their wish list. Billions are being invested in infrastructure, technology and research to modernize the healthcare systems in emerging market countries. This is giving a greater swath of the population access to better healthcare. Meanwhile rapid population aging is also stoking demand for healthcare. In 30 years' time there will be 400 to 500 million people over 60 in China alone, and they will have a growing need for modern health services and medicines.

Japan, which has been referred to as "the world's demographic laboratory", has championed cutting-edge innovation for decades. The Land of the Rising Sun boasts technology leadership in numerous fields, ranging from therapeutic antibody technology, immunotherapy and robotics to digitalization, diagnostics and medical imaging systems.

The fund offers defensive access to Asian emerging markets as well as exciting investment opportunities in technology leaders throughout the entire region. It invests in the entire healthcare system value chain, from generic drug producers and biotechnology companies to medical device manufacturers and digital health specialists.

Source: Bellevue Asset Management, 31.10.2021;  
 For illustrative purposes only. Holdings and allocations are subject to change. Any reference to a specific company or security does not constitute a recommendation to buy, sell, hold or directly invest in the company or securities. Where the subfund is denominated in a currency other than an investor's base currency, changes in the rate of exchange may have an adverse effect on price and income.

**Risk and return profile**

The Fund's objective is to generate an attractive return over a long-term horizon. It is therefore particularly suited to investors with an investment horizon of at least 5 years who want to diversify their portfolio with selective exposure to the healthcare sector in Asia and who are willing to accept the risks typically associated with stocks in this sector.



This fund is assigned to this category, as its share price fluctuates severely and both the risk of loss and the opportunities for profit can therefore be high. The calculation of the risk and earnings profile is based on simulated/historical data, which cannot be used as a reliable indication of the future risk profile. The classification of the fund may change in future and does not constitute a guarantee. Even a fund classed in category 1 does not constitute a completely risk-free investment. There can be no guarantee that a return will be achieved or that a substantial loss of capital will not be incurred. The overall risk exposure may have a strong impact on any return achieved by the fund or subfund. For further information please refer to the fund prospectus or KIID.

**Liquidity risk**

The fund may invest some of its assets in financial instruments that may in certain circumstances reach a relatively low level of liquidity, which can have an impact on the fund's liquidity.

**Risk arising from the user of derivatives**

The fund may conclude derivatives transactions. This increases opportunities, but also involves an increased risk of loss.

**Currency risks**

The fund may invest in assets denominated in a foreign currency. Changes in the rate of exchange may have an adverse effect on prices and incomes.

**Operational risks and custody risks**

The fund is subject to risks due to operational or human errors, which can arise at the investment company, the custodian bank, a custodian or other third parties.

**Target market**

The fund is suitable for retail and professional investors in Austria, Germany, Luxembourg, Spain, United Kingdom, Italy (Inst.) and Switzerland.

**Chances**

- Access to defensive growth – Asia's emerging countries are facing aging populations and changing lifestyles.
- An interesting combination of investments in Asian emerging markets and Japanese cutting-edge technology.
- Broad spread across different sectors and company sizes in the Asia-Pacific healthcare industry.
- Attractive valuations compared with the projected medium to long-term growth.
- Bellevue Healthcare Team – top-performing pioneer in the management of healthcare portfolios in emerging markets.

**Inherent risks**

- The fund invests in equities. Equities are subject to price fluctuations and so are also exposed to the risk of price losses.
- Investing in emerging markets entails the additional risk of political and social instability.
- The fund invests in foreign currencies, which means a corresponding degree of currency risk against the reference currency.
- The subfund may invest in China A equities. This entails the risk of supervisory changes, volume caps and operating restrictions which may lead to a higher counterparty risk.
- The fund may invest a proportion of its assets in financial instruments that might under certain circumstances have a relatively low level of liquidity, which can in turn affect the fund's liquidity.

You can find a detailed presentation of the risks faced by this fund in the "Special Investment Risks" section of the sales prospectus.

**Management Team**



**Oliver Kubli, CFA**  
Portfolio Manager since inception of the fund



**Remo Krauer, CIIA**  
Portfolio Manager of the fund since 2018



**Dr. Cyrill Zimmermann**  
Portfolio Manager since inception of the fund

**Awards**



**Sustainability Profile – ESG**

<b>Norms-based exclusions:</b>	<input checked="" type="checkbox"/> Compliance UNGC, HR, ILO	<input checked="" type="checkbox"/> Controversial weapons
<b>ESG Risk Analysis:</b>	<input checked="" type="checkbox"/> ESG Integration	<input type="checkbox"/> Best-in-Class
<b>Stewardship:</b>	<input checked="" type="checkbox"/> Engagement	<input checked="" type="checkbox"/> Proxy Voting

**CO2 intensity (t CO2/mn USD sales):** 44.8 t (low)      MSCI ESG coverage: 94%  
**MSCI ESG Rating (AAA - CCC):** BBB      MSCI ESG coverage: 94%  
**EU SFDR 2019/2088 product category:** Article 8

Based on portfolio data as per 30.09.2021 (quarterly updates) – ESG data base on MSCI ESG Research and are for information purposes only; compliance with global norms according to the principles of UN Global Compact (UNGC), UN Guiding Principles for Business and Human Rights (HR) and standards of International Labor Organisation (ILO); no involvement in controversial weapons; ESG Integration: Sustainability risks are considered while performing stock research and portfolio construction; Best-in-class: systematic exclusion of "ESG laggards"; MSCI ESG Rating ranges from "leaders" (AAA-AA), "average" (A, BBB, BB) to "laggards" (B, CCC). Note: in certain cases the ESG rating methodology may lead to a systematic discrimination of companies or industries, the manager may have good reasons to invest in supposed "laggards". The CO2 intensity expresses MSCI ESG Research's estimate of GHG emissions measured in tons of CO2 per USD 1 million sales; for further information c.f. [www.bellevue.ch/en/corporate-information/sustainability](http://www.bellevue.ch/en/corporate-information/sustainability)

## Important information

This marketing communication relates to Bellevue Funds (Lux) (hereinafter the “Fund”), an investment company with variable capital “société à capital variable” (SICAV) under the current version of the Law of the Grand Duchy of Luxembourg of 10 August 1915 on commercial companies (“Law of 1915”) and is authorized under Part I of the Law of 17 December 2010 relating to undertakings for collective investment (“Law of 2010”) as an undertaking for collective investment (UCITS). Bellevue Asia Pacific Healthcare is a subfund of Bellevue Funds (Lux).

This marketing communication is issued by Bellevue Asset Management AG, which is an authorized asset manager subject to the supervision of the Swiss Financial Market Supervisory Authority (FINMA) and acts as an Investment Manager of the Fund. The Prospectus, statutes, the annual and half-yearly report, the share prices and further information about the Fund can be obtained free of charge in English and German from the management company of the Fund, Bellevue Asset Management AG, Seestrasse 16, CH-8700 Küsnacht, from the representative, paying, facilities and information agents mentioned below or online at [www.bellevue.ch](http://www.bellevue.ch). The Key Investor Information documents are available free of charge in the languages of the countries of distribution at [www.fundinfo.com](http://www.fundinfo.com).

This document is neither directed to, nor intended for distribution or use by, any person or entity who is a citizen or resident of any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. It is particularly not intended for US persons, as defined under Regulation S of the U.S. Securities Act of 1933, as amended. The information and data presented in this document are not to be considered as an offer to buy, sell or subscribe to any securities or financial instruments. The information, opinions and estimates contained in this document reflect a judgment at the original date of release and are subject to change without notice. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient and in particular tax treatment depends on individual circumstances and may be subject to change. This document is not to be relied upon in substitution for the exercise of independent judgment. Before making any investment decision, investors are recommended to ascertain if this investment is suitable for them in the light of their financial knowledge and experience, investment goals and financial situation, or to obtain specific advice from an industry professional. The details and opinions contained in this document are not to be considered as recommendation or investment advice. Every investment involves risk, especially with regard to fluctuations in value and return, and investors' capital may be at risk. If the currency of a financial product is different from your reference currency, the return can increase or decrease as a result of currency fluctuations. Past performance is no indicator for the current or future performance. The performance data are calculated without taking account of commissions and costs that result from subscriptions and redemptions. Commissions and costs have a negative impact on performance. For more information about the associated costs, please refer to the related costs and fees section of the prospectus. Any benchmarks/indices cited herein are provided for information purposes only. No benchmark/index is directly comparable to the investment objectives, strategy or universe of the subfund. The performance of a benchmark shall not be indicative of past or future performance of the subfund. Financial transactions should only be undertaken after having carefully studied the current valid prospectus and are only valid on the basis of the latest version of the prospectus and available annual and half-yearly reports. Please take note of the risk factors.

## Countries of distribution and local representatives

The Bellevue Funds (Lux) is registered and admitted for public distribution in AT, DE, LU, UK, ES, IT (Inst.) and CH.

**Austria:** Paying and information agent: ERSTE BANK der oesterreichischen Sparkassen AG, Am Belvedere 1, A-1100 Vienna

**Germany:** Information agent: ACOLIN Europe GmbH, Reichenaustrasse 11a-c, D-78467 Konstanz

**Spain:** Representative: Atl Capital, Calle de Montalbán 9, ES-28014 Madrid - CNMV under the number 938

**Switzerland:** The Bellevue Funds (Lux) SICAV is registered for public offering and distribution in Switzerland with the Swiss Financial Market Supervisory Authority. Representative agent in Switzerland: Waystone Fund Services (Switzerland) SA, Avenue Villamont 17, CH-1005 Lausanne. Paying agent in Switzerland: DZ PRIVATBANK (Schweiz) AG, Münsterhof 12, P.O. Box, CH-8022 Zürich. You can obtain the sales prospectus, Key Investor Information Document (“KIID”), statutes and the current annual and half-yearly reports, the current share prices and further information about the fund free of charge in German from the management company Bellevue Asset Management AG, Seestrasse 16, CH-8700 Küsnacht, the representative agent in Switzerland or online at [www.bellevue.ch](http://www.bellevue.ch). In respect of the units distributed in or from Switzerland, the place of performance and jurisdiction is at the registered office of the representative agent.

Copyright©2021 Bellevue Asset Management, Inc. All rights reserved. Citywire information is proprietary and confidential to Citywire Financial Publishers Ltd (“Citywire”), may not be copied and Citywire excludes any liability arising out its use.

© 2021 MSCI ESG Research LLC. Reproduced by permission. Although Bellevue Asset Management information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the “ESG Parties”), obtain information from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness of any data herein. None of the ESG Parties makes any express or implied warranties of any kind, and the ESG Parties hereby expressly disclaim all warranties of merchantability and fitness for a particular purpose, with respect to any data herein. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein. Further, without limiting any of the foregoing, in no event shall any of the ESG Parties have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

The most important terms are explained in the glossary at [www.bellevue.ch/en/glossary](http://www.bellevue.ch/en/glossary)